Featured Research

from universities, journals, and other organizations

People without spouses under-represented in Alzheimer's clinical trials

Date:
December 19, 2012
Source:
American Academy of Neurology (AAN)
Summary:
A new study suggests that people without a spouse are represented less in Alzheimer's disease clinical trials compared to people with spouses.

A new study suggests that people without a spouse are represented less in Alzheimer's disease clinical trials compared to people with spouses. The study is published in the December 19, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

"Nationwide, half of all unpaid Alzheimer's disease caregivers are under the age of 50 and as many as 68 percent are the children, children-in-law or grandchildren of these patients," said study author Joshua D. Grill, PhD, Assistant Professor of Neurology at the UCLA Mary S. Easton Center for Alzheimer's Disease Research and a member of the American Academy of Neurology. "In contrast, in our analyses, 67 percent of the 2,041 Alzheimer's clinical trial participants had a spouse as their study partner. We found that there were several differences between people with spouse and adult child study partners that could affect the results of the trials and interpretations of those results."

Grill adds that factors such as race and caregiver attitude may also impact recruitment to trials. For example, only five percent of participants across the trials were Hispanic and those with an adult child study partner were twice as likely as those with spouse partners to be Hispanic. In addition, six percent of participants were African-American and those with adult child study partners were nearly three times as likely to be African-American as those with spouse study partners.

For the study, the research team categorized people with Alzheimer's disease based on the type of study partner they had -- either spouse, adult child or other study partners -- from six clinical trials conducted by the Alzheimer's Disease Cooperative Study.

In addition to the differences in enrollment, they found that participants with other study partners were at increased risk to drop out of studies.

After considering other factors, the risk of dropout for the "other" study partner group was 70 percent higher than that for the "spouse" study partner group.

The study was supported by the National Institute on Aging, the Sidell-Kagan Foundation and the Marian S. Ware Alzheimer Program.

To learn more about Alzheimer's disease, visit http://www.aan.com/patients.


Story Source:

The above story is based on materials provided by American Academy of Neurology (AAN). Note: Materials may be edited for content and length.


Journal Reference:

  1. J. D. Grill, R. Raman, K. Ernstrom, P. Aisen, J. Karlawish. Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology, 2012; DOI: 10.1212/WNL.0b013e31827debfe

Cite This Page:

American Academy of Neurology (AAN). "People without spouses under-represented in Alzheimer's clinical trials." ScienceDaily. ScienceDaily, 19 December 2012. <www.sciencedaily.com/releases/2012/12/121219173950.htm>.
American Academy of Neurology (AAN). (2012, December 19). People without spouses under-represented in Alzheimer's clinical trials. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/12/121219173950.htm
American Academy of Neurology (AAN). "People without spouses under-represented in Alzheimer's clinical trials." ScienceDaily. www.sciencedaily.com/releases/2012/12/121219173950.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins